Sporos BioDiscovery to Present at the Oppenheimer 33rd Annual Healthcare Conference

HOUSTON–(BUSINESS WIRE)–Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic programs targeting cancer vulnerabilities in the tumor and tumor microenvironment, today announced the company’s Executive in Residence, Stephen Rubino, Ph.D., will present a company overview on Wednesday, March 15, 2023, at 12:40 p.m. ET at the Oppenheimer 33^rd Annual Healthcare Conference, which will take place virtually.

To access the live webcast of this presentation, please select this link, or visit the News & Events page of Sporos Bioventures website www.sporosbioventures.com. A replay of the webcast will be available on the website for 90 days following the event.

About Sporos BioDiscovery

Sporos BioDiscovery, Inc. is a biotechnology research & development company with a diversified pipeline of several small molecule precision oncology therapeutic programs in development, including its lead candidate SPR1, a novel TEAD inhibitor program. Sporos BioDiscovery is a wholly-owned affiliate company of Sporos Bioventures, LLC, a private biotechnology company focused on transforming the drug development process across oncology.

Contacts

Media and Investor Contact
Lauren Stival Hopfer

[email protected]
201.841.6116